Revolution Medicines (FRA:42Z) OCF Margin %: 0.00% (As of Mar. 2026)

What is Revolution Medicines OCF Margin %?

Revolution Medicines FRA:42Z +1.46% 36 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:42Z with a GF Score™ of 36/100 and a GF Value™ of €0.39 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Revolution Medicines ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Revolution Medicines's Cash Flow from Operations for the three months ended in Mar. 2026 was €-306.35 Mil. Revolution Medicines's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Revolution Medicines's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Revolution Medicines's current OCF Yield % is -2.73%.

The historical rank and industry rank for Revolution Medicines's OCF Margin % or its related term are showing as below:

During the past 9 years, the highest OCF Margin % of Revolution Medicines was 6.02%. The lowest was -3027.39%. And the median was -366.79%.

FRA:42Z's OCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Revolution Medicines OCF Margin % Related Terms

Revolution Medicines OCF Margin % Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines OCF Margin % Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-500.78

-634.26

-3,027.36

0.00

Revolution Medicines Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

36GF Score

Revolution Medicines Inc FRA:42Z

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Revolution Medicines OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Revolution Medicines's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-766.671	/	0
	=	%

Revolution Medicines's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-306.353	/	0
	=	%

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 0.00% mean?

Revolution Medicines (FRA:42Z) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Revolution Medicines and its competitors. According to the industry distribution chart, Revolution Medicines ranks #999999 out of 958 companies in the Biotechnology industry.

Is Revolution Medicines' OCF Margin % too high?

Revolution Medicines' current OCF Margin % is 0.00%. Based on the distribution chart, Revolution Medicines ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revolution Medicines has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Revolution Medicines' OCF Margin % compare to ONC and ALNY?

According to the Biotechnology industry distribution chart, Revolution Medicines ranks #999999 out of 958 companies for OCF Margin %. This places Revolution Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Revolution Medicines stock overvalued right now?

Based on GuruFocus' analysis, Revolution Medicines (FRA:42Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.39, compared to a current price of €159.50 — trading 40797.4% above its estimated fair value. The current OCF Margin % is 0.00%. Revolution Medicines' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Revolution Medicines (FRA:42Z), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (FRA:42Z) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €159.50 is trading 40797.4% above its estimated GF Value™ of €0.39. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for FRA:42Z:

OCF Margin %: 0.00%
GF Value™: €0.39 vs. price of €159.50 (40797.4% above fair value)
GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Industry Healthcare Biotechnology

Comparable Companies ONC ALNY RPRX BNTX INSM ROIV INCY MRNA JAZZ ASND VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL XKRX:068270 HKSE:01801 HKSE:02269 OCSE:GMAB

Other Exchanges RVMD:USA 1RVMD:Italy 42Z:Germany

Address 700 Saginaw Drive, Redwood City, CA, USA, 94063

Website https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

36GF Score

Get the complete analysis for FRA:42Z

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€159.50

Price

€0.39

GF Value

View FRA:42Z Analysis

See OCF Margin % data for all stocks →